Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 9592 (Primary) ; Osimertinib (Primary)
  • Indications Carcinoma; Head and neck cancer; Mouth neoplasm; Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms EGRET
  • Sponsors AstraZeneca

Most Recent Events

  • 21 May 2025 Planned End Date changed from 24 Dec 2025 to 22 Jan 2026.
  • 21 May 2025 Planned primary completion date changed from 24 Dec 2025 to 22 Jan 2026.
  • 04 Feb 2025 Planned number of patients changed from 162 to 228.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top